AAD at the American Association of Bovine Practioners trade show.

Recent Accomplishments

AAD has been on the move since establishing proof of our concept. Here’s a sampling of our recent accomplishments:

2009

Jan

AAD’s first product, QuickSmear™ rapid differential slide, is launched at the National Mastitis Council Meeting in Charlotte, NC for research with differential cell counts.

Feb

AAD gathers producer input at World Ag Expo in Tulare, CA.

Mar

Series A Investment opportunity extended to June 30, 2009.

2008

Jan

AAD gathers input on better data for management decisions at Thought Leader Panel during National Mastitis Council Meeting in New Orleans.

May

AAD successfully completes definitive technology licensing agreement.

Jul

Value of milk leukocyte differential patterns was featured in well-received oral presentation at the World Buiatrics Congress Meeting in Budapest, Hungary. “Milk Leukocyte Population Patterns in Relation to Milk Fraction, Lactation Stage, and Udder Health” by Ariel Rivas, PhD, DVM. See the abstract (PDF) and presentation (PDF).

Sept

AAD staffed its first commercial exhibit booth and conducted live demonstrations at the American Association of Bovine Practioners’ Annual Meeting in Charlotte, NC. AAD technology was also featured in the Fresh cow monitoring on day three post partum and milk production poster. Practitioner survey highlights need for AAD technology.

AAD technology featured in paper in Europe at The Hague, Netherlands: “Multi-dimensional diagnosis of intramammary infections: a 3-herd evaluation”.

Oct

“Cellular Immunity as an Open-ended, Institutional Strategic Expertise-the case for Bovine Mastitis” presented at the University of Gottingen, Germany.

AAD Annual Shareholders Meeting.

Dec

AAD presented a poster at the 6th Annual One Medicine Symposium in Research Triangle Park. This innovative symposium combines a veterinary and human medicine approach to current medical issues. “Integrating technologies, methods, and multi-dimensional data to generate early, cost effective, space- and population-specific responses against zoonoses – the case of avian influenza (H5N1)” implied a use for AAD’s proprietary technology in these issues.